A brief insight into systemic lupus erythematosus pathogenesis

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Mar 31, 2016
DOI: https://doi.org/10.22551/2016.10.0301.10066
Tudor Azoicai Irina Draga Caruntu

Abstract

Systemic lupus erythematosus is an autoimmune disease which afflicts many systems. The precise pathogenesis is still unclear, but strong evidences sustain a multifactorial mechanism, based on the interaction of various genetic, epigenetic, environment, hormonal and immune-regulatory factors. Nowadays, the research interest focuses on cellular and molecular alterations, as results of the complexity of apoptotic process and immune responses acting as initiators and leading to tissue injury. The paper points out on key pathogenic cells, molecules and processes involved in SLE pathogenesis, namely B and T lymphocytes, mast cells, apoptosis, complement system and oxidative stress.

##plugins.themes.bootstrap3.article.details##

Keywords

systemic lupus erythematosus, pathogenesis, B/T lymphocytes, apoptosis, mast cells, complement system, oxidative stress

References
1. Doria A, Zen M, Bettio S, et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev 2012; 12:22-30.
2. Singh RP, Waldron RT, Hahn BH. Genes, tolerance and systemic autoimmunity. Autoimmun Rev 2012; 11:664-669.
3. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58(22):15-25.
4. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58(1):26-35.
5. Abdwani R, Rizvi SG, El-Nour I. Childhood systemic lupus erythematosus in Sultanate of Oman: demographics and clinical analysis. Lupus 2008; 17:683-686.
6. Barron KS, Silverman ED, Gonzales J, Reveille JD. Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1993; 36:348-354.
7. Font J, Cervera R, Espinosa G, et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998; 57:456-459.
8. Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008; 152:550-556.
9. Hoffman IE, Lauwerys BR, De Keyser F, et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 2009; 68:412-415.
10. Mahmoud SS, Bazaraa HM, Lotfy HM, Abd-El-Aziz DM. Renal involvement in childhood-onset systemic lupus erythematosus in Egypt. Rheumatol Int 2012; 32:47-51.
11. Jacobsen S, Petersen J, Ullman S, et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clin Rheumatol 1998; 17:468-477.
12. Seligman VA, Lum RF, Olson JL, et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002; 112:726-729.
13. Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus - an update. Curr Op Immunol 2012; 24:651-657.
14. Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nature Rev Nephrol 2015; 11:329-341.
15. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358(9):929-939.
16. Crow MK. Collaboration, genetic associations, and lupus erythematosus. N Engl J Med 2008; 358(9):956-961.
17. Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis 2014; 73:1601-1606.
18. Shah D, Mahajan N, Sah S, et al. Oxidative stress and its biomarkers in systemic lupus erythematosus. J Biomed Sci 2014; 21(1):23.
19. Wu T, Qin X, Kurepa Z, et al. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest 2007; 117:2186-2196.
20. Sang A, Zheng Y Y, Morel L. Contributions of B cells to lupus pathogenesis. Mol Immunol 2014; 62:329–338.
21. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med 1993; 177:999-1008.
22. Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med 1993;177:1009-1020.
23. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377.
24. Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008; 28:18-28.
25. Chan TD, Brink R. Affinity-based selection and the germinal center response. Immunol Rev 2012; 247:11-23.
26. Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Ann Rev Immunol 2007; 25:419-441.
27. Rifkin IR, Leadbetter EA, Beaudette BC, et al. Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. J Immunol 2000; 165:1626-1633.
28. Crispín JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:317-325.
29. Liossis SN, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated proteintyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 1998; 101:1448-1457.
30. Enyedy EJ, Nambiar MP, Liossis SN, et al. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:1114-1121.
31. Krishnan S, Juang YT, Chowdhury B, et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 2008; 181:8145-8152.
32. Deng GM, Liu L, Bahjat FR, et al. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010; 62:2086-2092.
33. Strasser A, Jost P, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30:180–192.
34. Blank U, Essig M, Scandiuzzi L, et al. Mast cells and inflammatory kidney disease. Immunol Rev 2007; 217:79-95.
35. Eddy AA. Mast cells find their way to the kidney. Kidney Int 2001; 60:375-377.
36. Pelletier C, Guerin-Marchand C, Iannascoli B, et al. Specific signaling pathways in the regulation of TNF-alpha mRNA synthesis and TNF-alpha secretion in RBL-2H3 mast cells stimulated through the high affinity IgE receptor. Inflamm Res 1998; 47:493-500.
37. Lin L, Gerth AJ, Peng SL. Susceptibility of mast cell-deficient W/Wv mice to pristane-induced experimental lupus nephritis. Immunol Lett 2004; 91:93-97.
38. Charles N, Hardwick D, Daugas E, et al. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 2010; 16:701-707.
39. Sekine H, Ruiz P, Gilkeson GS, Tomlinson S. The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol 2011; 49(1–2):317-323.
40. Wang G, Pierangeli SS, Papalardo E, et al. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010; 62(7):2064-2072.
41. Ben Mansour R, Lassoued S, Elgaied A, et al. Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 2010; 39(3):247-253.
42. Perl A. Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity 2010; 43(1):1-6.
43. Hassan SZ, Gheita TA, Kenawy SA, et al. Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis 2011; 14(4):325-331.
44. Gheita TA, Kenawy SA. Measurement of malondialdehyde, glutathione, and glutathione peroxidase in SLE patients. Methods Mol Biol 2014; 1134:193-199.
45. Sekine H, Kinser TT, Qiao F, et al. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 2011; 63:1076-1085.
46. Kerboua KE, Boumediene A, Haiba F, Batouche D. The alternative complement pathway activity may depend on plasma malondialdehyde level in systemic lupus erythematosus patients: Preliminary results. Egypt Rheumatol 2016; DOI: 10.1016/j.ejr.2016.02.003.
47. Oates JC. The biology of reactive intermediates in systemic lupus erythematosus. Autoimmunity 2010; 43:56–63.
48. Perl A. Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogrens syndrome. Curr Opin Rheumatol 2009; 21(5):443-447.
How to Cite
Azoicai, T., & Caruntu, I. D. (2016). A brief insight into systemic lupus erythematosus pathogenesis. Archive of Clinical Cases, 3(1), Arch Clin Cases 2016; 3(1):37-41. https://doi.org/10.22551/2016.10.0301.10066
Issue
Vol. 3 No. 1 (2016)
Section
Reviews

Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.

Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.

Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.

How to Cite

Azoicai, T., & Caruntu, I. D. (2016). A brief insight into systemic lupus erythematosus pathogenesis. Archive of Clinical Cases, 3(1), Arch Clin Cases 2016; 3(1):37-41. https://doi.org/10.22551/2016.10.0301.10066